Design Therapeutics Inc (DSGN)

$DSGN favorable cash to debt ratio, no position yet.. watch for now and try to buy low

$DSGN Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

$DSGN Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

$DSGN Is my chart glitching? DSGN is at $7.48 pre market? https://finance.yahoo.com/quote/DSGN/?guccounter=1

$DSGN Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy. https://www.biospace.com/press-releases/design-therapeutics-announces-favorable-phase-1-data-for-dt-168-supporting-advancement-into-phase-2-biomarker-trial-for-patients-with-fuchs-endothelial-corneal-dystrophy

$LXEO This is 1 of 4 Fredrich’s Axtasia stocks. the others being $DSGN $VYGR & $LRMR The reason for the drop today is included in the news that no real catalyst will be avail until late 2026 early 2027

$DSGN Digging deep into DSGN's GeneTAC platform. Pipeline looks promising for rare genetic disorders. FA and FECD trials could be game changers. Watching closely for proof-of-concept data. Might start a small position if Phase 1 results look clean. Biotech is wild but this feels different. R&D spend looks strategic. Potential breakout incoming. great article: https://beyondspx.com/article/design-therapeutics-dsgn-a-pioneering-biotech-tackling-genetic-disorders-with-innovative-genetac-r-platform

$DSGN Design Therapeutics sees cash runway into 2029 Cash, cash equivalents and marketable securities were $245.5M as of December 31, 2024, which the company expects to fund its planned operating expenses into 2029.

$DSGN Design Therapeutics provides corporate highlights, anticipated milestones Friedreich Ataxia: Design has initiated dosing in a Phase 1 clinical trial in healthy volunteers in Australia to evaluate the safety and pharmacokinetics of single ascending doses of DT-216P2 via multiple routes of administration. A Phase 1/2 multiple ascending dose clinical trial to assess safety, PK and pharmacodynamics in FA patients is anticipated to begin in mid-2025. Data based on twelve weeks of DT-216P2 dosing in patients is anticipated in 2026. Fuchs Endothelial Corneal Dystrophy: Design has completed dosing in a Phase 1 MAD clinical trial of DT-168 in healthy volunteers and expects to report data in the first half of 2025. The company achieved its enrollment goal for the observational study by recruiting and completing baseline assessments on approximately 250 FECD patients. Based on the baseline characteristics data, Design has chosen approximately 100 patients for future follow-up visits. Pipeline programs: Design continues to advance preclinical work toward the selection of a development candidate for myotonic dystrophy type-1 later in 2025. Preclinical characterization of several candidate molecules also continues in Huntington's disease.

$DSGN Design Therapeutics reports Q4 EPS (24c), consensus (27c) "Thanks to the progress we have achieved so far this year, the first half of 2025 will be a busy one for Design, with data expected from our Phase 1 trial in FECD and the advancement of clinical activities in our FA program," said Pratik Shah, CEO. "We believe these programs lead a pipeline of GeneTAC small molecules capable of transforming the status quo in genomic medicines, with the potential for multiple clinical proof-of-concept data sets over the next few years."